Navigation Links
WuXi AppTec Welcomes Three Senior Professionals
Date:3/24/2009

SHANGHAI, March 24 /PRNewswire-Asia/ -- WuXi AppTec (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced the addition of three key senior professionals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Brian J. Xu has joined WuXi AppTec as Vice President of Toxicology and Head of the Safety Evaluation Center at Suzhou, reporting to Dr. Ge Li, Chairman and Chief Executive Officer. Dr. Xu is an American Board Certified Toxicologist (DABT) and had worked previously in Merck, Roche, Schering-Plough and Enzon. Dr. Xu received his Ph.D. from George Washington University and did post-doctoral research at Yale University.

Dr. Yang-Dar Yuan has joined the company as Vice President of Operation and Head of Pathology of the Safety Evaluation Center, reporting to Dr. Brian Xu. Dr. Yuan is a member of American College of Veterinary Pathologists (ACVP), a member of the American College of Laboratory Animal Medicine and an American Board Certified Toxicologist (DABT). He brings more than 30 years of rich experiences in preclinical safety assessment and drug development. Dr. Yuan had worked previously in Upjohn, Pfizer, Allergan and Vitae Pharmaceutical. Dr. Yuan received a D.V.M. from National Taiwan University and a Ph.D. in Veterinary Pathology from Cornell University.

Mr. Robert Coldreck has joined the company as Head of GLP (Good Laboratory Practice) QA (Quality Assurance). Mr. Coldreck had previously worked in Novartis, most recently as Director of Laboratory and Preclinical Quality Assurance-North America and Asia. He brings more than 30 years of rich experience in GLP quality assurance. Mr. Coldreck received his B.S. in Biology from Fairleigh Dickinson University.

"I am delighted to welcome Brian, Yang-Dar and Bob to our management team to lead our preclinical services," said Dr. Li. "With their rich experience and knowledge in GLP preclinical studies and their strong leadership in respective fields, WuXi continues to build a world-class preclinical service platform to serve our customers' demands."

About WuXi AppTec and WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Sherry Shao
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4002
     Email: pr@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
2. WuXi PharmaTech Completes Acquisition of AppTec
3. WuXi AppTec VP and GM Invited to Join the AAMI Standards Board
4. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
5. WuXi AppTec Selects H-Cube from ThalesNano for Laboratory-based Hydrogenation
6. Professor K. C. Nicolaou Speaks at WuXi AppTec
7. Medicsight Welcomes U.S. Initiative to Reimburse CT Colonography for Early Detection of Colorectal Cancer
8. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
9. BioSpace Career Fair in San Francisco Welcomes Over 1,000 Bioscience Professionals
10. FCP Welcomes Mark Scherling
11. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Dallas-Fort Worth, Texas (PRWEB) , ... September 20, 2017 , ... ... people, stem cell therapy succeeded after standard medicine failed. Many of these people had ... - Progress, Not Regression Free Download (pdf) , “Neil ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... a standard fume hood and a high-performance fume hood. Along with the advantages ... and applications for ductless vs. ducted hoods in the laboratory. , Attendees will ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... an biological outbreak is about to be eliminated, said Lyle Probst, President, CEO ... FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample ...
(Date:9/19/2017)... Austin, TX (PRWEB) , ... ... ... New York State Department of Financial Services (NYS DFS) cybersecurity ... all regulated banking, finance and insurance organizations operating in the state (“Covered ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):